Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • DAPT (GSI-IX): Selective γ-Secretase Inhibitor for Notch ...

    2026-01-23

    DAPT (GSI-IX): Selective γ-Secretase Inhibitor for Notch and Amyloid Research

    Executive Summary: DAPT (GSI-IX), provided by APExBIO, is an orally bioavailable γ-secretase inhibitor with nanomolar potency (IC50 = 20 nM in HEK 293 cells) and high selectivity for blocking Notch and amyloid precursor protein processing (APExBIO product page). It inhibits the generation of amyloid-β peptides, including Aβ40 and Aβ42, and modulates Notch signaling, thereby impacting differentiation, apoptosis, and autophagy in diverse cell types (Oh et al., 2025). DAPT is a well-characterized research tool in neurodegenerative, autoimmune, and oncology studies, and supports reproducible cell-based assays at concentrations as low as 1.0 μM. It is soluble in DMSO and ethanol, stable at -20°C, and enables precise dissection of γ-secretase-dependent signaling pathways. Each of these claims is supported by peer-reviewed literature and product validation data.

    Biological Rationale

    γ-Secretase is a multi-subunit protease complex essential for the intramembrane cleavage of type I transmembrane proteins, most notably amyloid precursor protein (APP) and Notch receptors. Aberrant γ-secretase activity is implicated in the pathogenesis of Alzheimer's disease through increased production of neurotoxic amyloid-β (Aβ) peptides. Notch signaling, regulated by γ-secretase-mediated cleavage, plays a central role in cell fate determination, immune regulation, and tumorigenesis (Oh et al., 2025). Inhibition of γ-secretase with agents like DAPT (GSI-IX) allows researchers to dissect these pathways, supporting discovery in neurodegeneration, cancer biology, and immune modulation. The ability to selectively inhibit these proteolytic events provides a powerful tool for both basic mechanistic studies and preclinical therapeutic development. DAPT (GSI-IX) is chosen for its high selectivity, potency, and compatibility with in vitro and in vivo models (APExBIO).

    Mechanism of Action of DAPT (GSI-IX)

    DAPT (GSI-IX) binds to the active site of the γ-secretase complex, blocking its proteolytic activity. This inhibition prevents the cleavage of key substrates such as APP and Notch, reducing the formation of Aβ40 and Aβ42 peptides and the Notch intracellular domain (NICD). The IC50 for γ-secretase inhibition in HEK 293 cells is 20 nM. In cell-based assays, DAPT reduces Aβ release with an IC50 of 115 nM. By interrupting Notch receptor processing, DAPT disrupts downstream signaling cascades that influence stem cell differentiation, proliferation, apoptosis, and autophagy. These effects are dose- and context-dependent, with 1.0 μM being effective for inhibition of proliferation in SHG-44 human glioma cells. In vivo, DAPT at 10 mg/kg/day subcutaneously reduces tumor angiogenesis markers in Balb/C mice (APExBIO). The molecular weight is 432.46, and it is soluble at ≥21.62 mg/mL in DMSO and ≥16.36 mg/mL in ethanol when ultrasonicated, but insoluble in water. The compound is stable at -20°C for long-term storage as a solid, while solutions should be kept below -20°C and used promptly to ensure integrity.

    Evidence & Benchmarks

    • DAPT (GSI-IX) inhibits γ-secretase in HEK 293 cells with an IC50 of 20 nM under standard culture conditions (APExBIO).
    • Reduces Aβ40 and Aβ42 secretion in cell-based assays, with an IC50 of 115 nM (APExBIO).
    • Blocks Notch signaling in diverse human and murine cell types, affecting differentiation and apoptosis (Oh et al., 2025).
    • Inhibits proliferation of SHG-44 human glioma cells in vitro at 1.0 μM (APExBIO).
    • Reduces tumor angiogenesis markers in Balb/C mice at 10 mg/kg/day (subcutaneous) (APExBIO).
    • Used as a benchmark γ-secretase inhibitor in studies of latent HSV-1 infection in human iPSC-derived neurons (Oh et al., 2025).

    Applications, Limits & Misconceptions

    DAPT (GSI-IX) is extensively utilized in research on Alzheimer's disease, cancer, autoimmune disorders, and cell fate determination. It facilitates the study of Notch signaling and amyloidogenic pathways in vitro and in vivo. DAPT is a proven reagent for apoptosis, autophagy, and proliferation assays, and is compatible with established protocols (see scenario-driven assay guidance; this article extends those practical details with updated benchmarks and mechanistic context). It is also valuable in disease modeling and regenerative medicine research (see advanced cell fate modulation review; here, we clarify limits for translational application).

    However, DAPT is not selective for specific Notch receptors and does not distinguish between APP and Notch substrate inhibition. Its efficacy is context- and concentration-dependent, and it does not inhibit other protease classes. Additionally, pharmacokinetic properties in humans are not established, and off-target effects may occur at higher doses.

    Common Pitfalls or Misconceptions

    • DAPT (GSI-IX) is not a pan-protease inhibitor: It selectively inhibits γ-secretase but does not affect serine or cysteine proteases (APExBIO).
    • Not suited for water-based preparations: DAPT is insoluble in water; use DMSO or ethanol with ultrasonic assistance for stock solutions.
    • Does not distinguish between APP and Notch substrate inhibition: It blocks γ-secretase activity for all substrates processed by the complex.
    • Not a therapeutic agent: DAPT is for research use only; pharmacokinetics and safety in humans are not established.
    • Potency is cell-type and assay dependent: Optimal concentrations must be determined empirically for each system.

    Workflow Integration & Parameters

    DAPT (GSI-IX) seamlessly integrates into cell-based assays for apoptosis, proliferation, and autophagy. Dissolve DAPT at ≥21.62 mg/mL in DMSO or ≥16.36 mg/mL in ethanol using ultrasonic assistance; avoid water. Store solid at -20°C and use fresh solutions for reproducibility. For in vitro assays, concentrations between 20 nM and 1.0 μM are effective. In vivo, subcutaneous dosing at 10 mg/kg/day in rodents has demonstrated target engagement and biological effects. Use in combination with cell viability or apoptosis markers to validate pathway inhibition. For advanced guidance on troubleshooting and maximizing reproducibility, see this troubleshooting resource, which this article updates with new benchmarks and mechanistic clarity.

    Conclusion & Outlook

    DAPT (GSI-IX) from APExBIO is a validated, selective γ-secretase inhibitor that empowers researchers to dissect Notch and amyloidogenic pathways in disease models. Its robust performance, ease of workflow integration, and clear mechanistic action make it indispensable in Alzheimer's, cancer, and immune research. Ongoing studies continue to refine its applications and uncover new roles in cell fate and regenerative biology. Future research should address substrate selectivity and translational safety to maximize its impact as a research tool.